Drug treatment of personality disorders

被引:2
作者
Pelissolo, A. [1 ,2 ]
Jost, F. [3 ]
机构
[1] Hop La Pitie Salpetriere, AP HP, Serv Psychiat Adulte, F-75013 Paris, France
[2] Hop La Pitie Salpetriere, AP HP, UPMC, F-75013 Paris, France
[3] Hop Corentin Celton, AP HP, Psychiat Serv, F-92130 Issy Les Moulineaux, France
来源
ANNALES MEDICO-PSYCHOLOGIQUES | 2011年 / 169卷 / 09期
关键词
Antidepressant; Antipsychotic; Borderline personality disorder; Mood stabilizor; Personality disorder; IMPULSIVE AGGRESSIVE-BEHAVIOR; DOUBLE-BLIND; DIVALPROEX; OLANZAPINE; EFFICACY;
D O I
10.1016/j.amp.2011.09.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug treatment of personality disorders is less developed than are psychological treatments in this area, but they are a logical prolongation of psychobiological models of personality and temperament, and respond to the need of many clinicians in front of difficult patients. The results obtained in the field of pharmacotherapy of personality disorders can be classified according to DSM-IV axis-II categorization. In anxious personalities (cluster C), some isolated studies suggest a favourable effect of antidepressants on obsessive-compulsive dimension, on avoidant personality disorder, and on inhibition and trait-anxiety, especially when serotoninergic agents are used. Few studies have been conducted in cluster A personality disorders, and some are in favour of the interest of low doses of antipsychotic drugs in this group. Most studies have been conducted in cluster B, and especially in antisocial and borderline personality disorders. Partial positive results have been obtained using various classes of drugs for dealing with aggression and impulsive behaviors, including lithium, beta-blockers, carbamazepine, valproate, antipsychotic drugs, and also SSRIs. Self-harm and suicidal behaviors seem to be partially but significantly improved by antidepressants and low doses of antipsychotics. Overall, the pharmacotherapy of personality disorder may lead in the future to the development of effective treatments, in complement to psychotherapy, for actually severe, chronic, and disabling disorder. (C) 2011 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:592 / 594
页数:3
相关论文
共 22 条
[11]   Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind, placebo-controlled study [J].
Nickel, MK ;
Muehlbacher, M ;
Nickel, C ;
Kettler, C ;
Gil, FP ;
Bachler, E ;
Egger, C ;
Anvar, J ;
Rother, WK ;
Loew, TH ;
Kaplan, P .
AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (05) :833-838
[12]   Increased activation in the right insula during risk-taking decision making is related to harm avoidance and neuroticism [J].
Paulus, MP ;
Rogalsky, C ;
Simmons, A ;
Feinstein, JS ;
Stein, MB .
NEUROIMAGE, 2003, 19 (04) :1439-1448
[13]  
PELISSOLO A, 2002, TROUBLES PERSONNALIT, P109
[14]  
PULL CB, 2002, TROUBLES PERSONNALIT, P81
[15]   Impulsive aggressive behavior: Open-label treatment with citalopram [J].
Reist, C ;
Nakamura, K ;
Sagart, E ;
Sokolski, KN ;
Fujimoto, KA .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (01) :81-85
[16]   Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study [J].
Schulz, S. Charles ;
Zanarini, Mary C. ;
Bateman, Anthony ;
Bohus, Martin ;
Detke, Holland C. ;
Trzaskoma, Quynh ;
Tanaka, Yoko ;
Lin, Daniel ;
Deberdt, Walter ;
Corya, Sara .
BRITISH JOURNAL OF PSYCHIATRY, 2008, 193 (06) :485-492
[17]  
SHEARD HM, 1976, AM J PSYCHIAT, V133, P1409
[18]   Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder [J].
Soler, J ;
Pascual, JC ;
Campins, J ;
Barrachina, J ;
Puigdemont, D ;
Alvarez, E ;
Pérez, V .
AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (06) :1221-1224
[19]   AMITRIPTYLINE VERSUS HALOPERIDOL IN BORDERLINES - FINAL OUTCOMES AND PREDICTORS OF RESPONSE [J].
SOLOFF, PH ;
GEORGE, A ;
NATHAN, RS ;
SCHULZ, PM ;
CORNELIUS, JR ;
HERRING, J ;
PEREL, JM .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1989, 9 (04) :238-246
[20]  
TYRER P, 1998, PSYCHIAT B, V22, P242, DOI 10.1192/pb.22.4.242